Literature DB >> 31423482

Adaptive Plasticity in the Retina: Protection Against Acute Injury and Neurodegenerative Disease by Conditioning Stimuli.

Jeffrey M Gidday1.   

Abstract

Although both preclinical and clinical conditioning studies in heart and brain lead the field of conditioning medicine, investigations of retinal conditioning still number more than 100. In this brief review, we highlight findings to date from animal and cell culture models of conditioning that provide demonstrated protection in acute and chronic retinal injury and disease models. The multitude of stimuli used to condition the retina, the signaling mediators and pathways identified, and the injury- and disease-resilient phenotypes documented are discussed herein, along with our recommendations for the kinds of studies needed to continue to advance this promising field. In our view, the robust protection afforded by these adaptive epigenetic responses to conditioning stress provides significant incentives for both furthering our investment in bench research and underwriting clinical trials, so that the full potential of this therapy can be realized.

Entities:  

Year:  2018        PMID: 31423482      PMCID: PMC6696944     

Source DB:  PubMed          Journal:  Cond Med        ISSN: 2577-3240


  123 in total

1.  Protection of photoreceptor cells in adult rats from light-induced degeneration by adaptation to bright cyclic light.

Authors:  F Li; W Cao; R E Anderson
Journal:  Exp Eye Res       Date:  2001-10       Impact factor: 3.467

2.  Ischemic preconditioning attenuates hypoperfusion after retinal ischemia in rats.

Authors:  J Lin; S Roth
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-11       Impact factor: 4.799

3.  ATP-sensitive potassium channels (K(ATP)) in retina: a key role for delayed ischemic tolerance.

Authors:  M Ettaiche; C Heurteaux; N Blondeau; M Borsotto; N Tinel; M Lazdunski
Journal:  Brain Res       Date:  2001-01-26       Impact factor: 3.252

4.  Mouse models of retinal ischemic tolerance.

Authors:  Yanli Zhu; Kevin K Ohlemiller; Belinda K McMahan; Jeffrey M Gidday
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-06       Impact factor: 4.799

5.  Inhibitory effect of ischemic preconditioning on leukocyte participation in retinal ischemia-reperfusion injury.

Authors:  A Nonaka; J Kiryu; A Tsujikawa; K Yamashiro; K Nishijima; K Miyamoto; H Nishiwaki; Y Honda; Y Ogura
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-09       Impact factor: 4.799

6.  Retinal ischemic preconditioning in the rat: requirement for adenosine and repetitive induction.

Authors:  B Li; S Roth
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-05       Impact factor: 4.799

7.  Signal transduction mechanisms involved in ischemic preconditioning in the rat retina in vivo.

Authors:  B Li; C Yang; D M Rosenbaum; S Roth
Journal:  Exp Eye Res       Date:  2000-06       Impact factor: 3.467

8.  Induction of heat shock protein 72 protects retinal ganglion cells in a rat glaucoma model.

Authors:  K H Park; F Cozier; O C Ong; J Caprioli
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-06       Impact factor: 4.799

9.  Late preconditioning in rat retina: involvement of adenosine and ATP-sensitive K(+) channel.

Authors:  K Sakamoto; M Kuwagata; T Nakahara; K Ishii
Journal:  Eur J Pharmacol       Date:  2001-04-20       Impact factor: 4.432

10.  Müller cells in the preconditioned retinal ischemic injury rat.

Authors:  T Nishiyama; S Nishukawa; M Tamai
Journal:  Tohoku J Exp Med       Date:  2000-08       Impact factor: 1.848

View more
  2 in total

1.  Peripheral Mechanisms of Remote Ischemic Conditioning.

Authors:  Jiwon Yang; Faariah Shakil; Sunghee Cho
Journal:  Cond Med       Date:  2019-02

2.  Effects of remote ischemic conditioning on sleep complaints in Parkinson's disease-rationale, design, and protocol for a randomized controlled study.

Authors:  Qiling Ji; Xuemei Wang; Wenbo Zhao; Melissa Wills; Ho Jun Yun; Yanna Tong; Lipeng Cai; Xiaokun Geng; Yuchuan Ding
Journal:  Front Neurol       Date:  2022-07-25       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.